Dr. Soliman Abdul Kader Fakeeh Hospital Co. vs DaVita Inc.
A head-to-head of Dr. Soliman Abdul Kader Fakeeh Hospital Co. (4017) and DaVita Inc. (DVA) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 4017 | DVA |
|---|---|---|
| Market Cap | 8.01B SAR | $15.21B |
| P/E (TTM) | 30.23 | 21.98 |
| Forward P/E | 21.07 | 11.63 |
| P/S | 2.59 | 0.91 |
| P/B | 2.51 | 15.64 |
| EV/EBITDA | 22.21 | 8.90 |
| Dividend Yield | — | — |
| Profit Margin | 8.77% | 5.65% |
| Gross Margin | 19.32% | 32.25% |
| Operating Margin | 6.16% | 14.74% |
| Revenue Growth (YoY) | -2.50% | +5.96% |
| FCF Yield | -2.30% | 12.00% |
| Debt / Equity | 20.66 | 1013.79 |
| Current Ratio | 1.65 | 1.42 |
Which is better: Dr. Soliman Abdul Kader Fakeeh Hospital Co. or DaVita Inc.?
- ✓Larger by market cap: DaVita Inc.
- ✓Cheaper valuation (lower P/E): DaVita Inc.
- ✓More profitable (net margin): Dr. Soliman Abdul Kader Fakeeh Hospital Co.
- ✓Faster revenue growth: DaVita Inc.
- ✓Higher free-cash-flow yield: DaVita Inc.
Across 12 available metrics, DaVita Inc. leads 8–4.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Dr. Soliman Abdul Kader Fakeeh Hospital Co. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.